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selective or non-selective and weak opioids (codeine, tramadol, dextropropoxyphene) 
was extracted and analysed. RESULTS: A total of 23 456 prescriptions were analysed, 
18 187 prescribed to adults [18–64 years] and 5 269 to elderly ≥65 years of age 
[65–101 years]. The proportion of NSAID prescriptions for non-selective plus selective 
Cox-2-inhibitors (Coxibs), did not change during the 5- year period, 91.1, 91.3, 91.4, 
92 and 91.5 % of patients were prescribed an NSAID. The proportion of prescriptions 
for traditional non-selective NSAIDs increased from 83.9% to 90.3 % from year 2004 
to 2008 among adult patients and from 69.7% to 78.7% among elderly. The propor-
tion of prescriptions for Coxibs decreased between 2004 and 2008 and were pre-
scribed to 3.6 % of patients in this study in 2008. Co-prescription of gastric protective 
therapy was made in 12–20 % of prescriptions with no differences between NSAID, 
Coxibs and non-NSAID. CONCLUSIONS: In this review of NSAID prescription 
utilization among patients with a diagnosis of musculoskeletal pain shows an extensive 
use of anti-inﬂammatory agents without co-prescription of gastro-protective medica-
tion. The impact of this high utilization of NSAIDs without co-prescription of gastro-
protective agents on the risk for upper gastro-intestinal complications warrants further 
evaluation.
PSY55
IS HOSPITAL EXPERIENCE ASSOCIATED WITH BETTER IN-HOSPITAL 
OUTCOMES AMONG SICKLE CELL PATIENTS WITH ACUTE CHEST 
SYNDROME: RESULTS FROM A NATIONAL DATABASE
Kamble S, Reed SD
Duke Clinical Research Institute, Durham, NC, USA
OBJECTIVES: Acute chest syndrome (ACS) is the leading cause of death and the 
second most common cause of hospitalization in patients with sickle cell disease 
(SCD), yet it is unclear whether hospital experience (i.e., volume) is associated with 
improved clinical and resource-use outcomes. In this study, we compared inpatient 
mortality, length of stay (LOS) and total costs between high- and low-SCD volume 
hospitals treating ACS patients. METHODS: Using the 2006–2007 Nationwide Inpa-
tient Sample (NIS), we identiﬁed ACS patients based on ICD-9-CM codes 517.3 (ACS) 
or 486 (pneumonia) among discharges with SCD (Clinical Classiﬁcation Code 61). 
SCD volume represented the average number of SCD discharges from a hospital per 
year over the 2-year study period. Given that majority of patients were treated in a 
relatively small number of hospitals, the top decile was selected to represent high 
volume hospitals. We used generalized estimating equations to evaluate whether 
hospital-level SCD experience was independently associated with inpatient mortality 
(binomial distribution, logit link), LOS (negative binomial distribution, log link) and 
costs (gamma distribution, log link) between volume groups while controlling for 
gender, age, payer, number of comorbidities, and hospital characteristics, including 
rural vs. urban location, teaching status, bed size, ownership type, and hospital region. 
RESULTS: Among 6,857 ACS discharges across 688 hospitals, 4154 and 2703 were 
treated in high- and low-volume hospitals, respectively. Median age was 22 in high-
volume hospitals and 29 in low-volume hospitals. In unadjusted analyses, inpatient 
mortality (0.9% vs. 1.7%, p = 0.004), mean LOS (6.9 vs. 7.4, p = 0.005), and mean 
costs ($11,358 vs. $12,013, p = 0.077) were lower in high vs. low volume hospitals. 
After adjustment for patient and hospital characteristics, hospital volume was no 
longer signiﬁcantly associated with inpatient outcomes. CONCLUSIONS: Hospital 
volume was not signiﬁcantly associated with inpatient mortality, LOS, and total costs 
among ACS patients.
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INFLIXIMAB INDUCTION PATTERNS AND THE IMPACT ON 
MAINTENANCE THERAPY PATTERNS
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OBJECTIVES: To assess induction and maintenance infusion patterns of inﬂiximab 
(IFX) treatment in ulcerative colitis (UC) patients receiving 1, 2, or 3 induction doses. 
METHODS: A retrospective analysis of medical claims from an administrative data-
base was conducted for UC patients newly starting IFX. Patients were required to 
have age ≥18 yrs, 2 diagnosis codes for UC, IFX index date between September 1, 
2005 and January 31, 2008, and ≥ 26 months of continuous enrollment (minimum 
12 months before and 14 months after the index date). Patients with select pre-index 
inﬂammatory disorders were excluded. The analysis evaluated induction (IFX doses 
during ﬁrst 56 days post-index) and maintenance (doses >56 days and <12 months 
post-induction). Persistence during maintenance was deﬁned by a medication posses-
sion ratio (MPR) of >80%. Results were stratiﬁed by the number of induction doses 
(1, 2, or 3). RESULTS: A total of 354 UC patients were included in the analyses: 
mean (SD) age of 44 (14) yrs; 48.3% female; 62.4% received IFX in the outpatient 
ofﬁce setting. There were 27, 83, and 244 patients in the 1, 2, and 3 induction dose 
groups, respectively. The overall mean (SD) number of days during the induction 
period was 35 (14), and days increased with the number of induction doses. During 
the maintenance period, patients received an overall mean (median) of 5 (6) infusions. 
The cohort receiving 3 induction infusions had the highest percentage of patients with 
an MPR > 80%. Infusion patterns for the ﬁrst year post-induction were consistent 
with recommended prescribing information, with a median of 56 days between infu-
sions. CONCLUSIONS: The majority of IFX patients received 3 induction doses. 
Induction and maintenance infusion patterns were consistent with prescribing recom-
mendations, especially for those patients receiving 3 induction doses. These data 
support administering 3 IFX doses during induction to ensure appropriate dosing and 
optimal medication adherence during maintenance.
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MAINTENANCE INFLIXIMAB DOSING AND ADMINISTRATION 
PATTERNS IN PATIENTS WITH CROHN’S DISEASE
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OBJECTIVES: U.S. Food and Drug Administration (FDA)-approved prescribing infor-
mation recommends inﬂiximab (IFX) administration at 0, 2, 6 and every 8 weeks with 
potential dose escalation based on patient response in Crohn’s Disease (CD) patients. 
Minimal real world dosing data are available in this population. This study describes 
IFX dosing patterns in patients with CD treated in an outpatient hospital setting. 
METHODS: A retrospective longitudinal analysis using the Premier PerspectiveTM 
Database, a U.S.-based hospital database, was conducted. Inclusion criteria were an 
outpatient hospital discharge CD diagnosis between July 1, 2000 and March 31, 2008, 
IFX-naïve (received no IFX in the prior 180 days), and ≥ 3 IFX doses within ≤56 days 
of the index infusion. Exclusion criteria included patients with other selected inﬂam-
matory diseases. Treatment duration was deﬁned as the time between the index and 
last IFX dose. Hospital outpatient dosing schedules were analyzed for the 4th through 
15th IFX dose, representing the ﬁrst two years of IFX maintenance treatment. 
RESULTS: A total of 1439 IFX-treated patients with CD were identiﬁed. Mean (SD) 
age was 42.8 (15.4) years; 59% were female. Mean (SD) treatment duration was 415 
(425) days. Patients received a mean (SD) of 8.4 (7.5) IFX administrations. Mean (SD) 
index IFX dose was 429 (152) mg. During the initial two years of maintenance IFX 
administration, the highest observed mean IFX dose represented a 10% increase 
during the maintenance period and a 13% increase compared to the index IFX dose. 
Median time between administrations was 56 days for all maintenance infusions. 
CONCLUSIONS: The mean IFX dose remained between 439 and up to 483 mg 
throughout the maintenance treatment. Administration schedule was consistent with 
FDA-approved prescribing information. These data suggest that IFX dosing patterns 
in CD patients remain relatively stable with minimal dose escalation occurring when 
administered in real world outpatient hospital settings.
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OBJECTIVES: To present the design of a lifetime Markov model that compares the 
cost-effectiveness of primary prophylaxis versus on-demand treatment with recombi-
nant factor VIII among children with severe hemophilia A. METHODS: Prophylactic 
infusions of rFVIII-FS have been shown to reduce the frequency of bleeding episodes 
and the risk of joint damage in children with hemophilia A with no pre-existing joint 
damage. Clinical studies have shown signiﬁcant improvement in outcomes with the 
use of prophylactic treatment, as well as apparent gains in health-related quality of 
life. However, recombinant clotting factors are also associated with relatively high 
cost. Using a lifetime Markov model, the cost-effectiveness of primary prophylaxis 
treatment was compared to on-demand treatment. This model is among the few that 
model long-term cost and effectiveness and is unique in that it takes into account the 
probability of inhibitor development, use of central venous access device (CVAD), and 
total bleeding risk including CNS and joint bleeds. Prophylactic treatment is assumed 
to be from birth until 16 years of age. Built in the model were also 5 health states: 
being alive, surgery, inhibitor development, disability and deceased. SUMMARY: 
From this model, cost-effectiveness estimations can be made for patients receiving 
on-demand treatment versus primary prophylaxis. Cost-effectiveness can vary by the 
frequencies of events between treatment arms, age where prophylaxis begins and ends, 
dose/frequency of factor VIII, cost of medications and key hospital-related events, and 
the probability of achieving speciﬁed clinical endpoints. CONCLUSIONS: The 
strengths and distinguishing characteristics of this model versus previously published 
hemophilia prophylaxis models include: long-term cost and effectiveness, probability 
of inhibitor development, use of CVAD, and CNS bleeds. There are a few study limita-
tions related to the lack of data for model assumptions. Obtaining stronger evidence 
for these parameters may substantiate or potentially improve the model results.
PSY59
USING PATIENT FOCUS GROUPS TO INFORM ECONOMIC MODELING: 
EXPERIENCE FROM A HEMOPHILIA PATIENT FOCUS GROUP
Lalla A1, Boer R1, Pocoski J2, Dean B1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Bayer HealthCare Pharmaceuticals, Inc., 
Wayne, NJ, USA
BACKGROUND: Decision modeling is commonly used to assess the cost-utility of 
drugs or technologies. For a real-world application, models should include aspects of 
the disease relevant to the patient. In recent years, patient focus groups have been used 
to help deﬁne health utility values. METHODS: Hemophilia patients attending the 
National Hemophilia Foundation’s 61st Annual Meeting were invited to participate 
in a focus group to inform the development of a decision model, evaluating prophy-
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lactic treatment of hemophilia. Patients and caregivers completed questionnaires and 
provided verbal feedback addressing several open-ended questions, including type and 
duration of bleeds, disability, impact of treatments on lifestyle and their perceptions 
about standard utility. RESULTS: Twenty-one patients or caregivers of children with 
bleeding disorders attended. Important implications for the model were noted: a) 
Patients reported that muscle bleeds can be more painful and last longer (ie, associated 
with lower utility) than joint bleeds, which are generally considered more disabling; 
b) Patients reported that the course (utility, improvement) of a typical bleed differs by 
the type of bleed (joint vs. muscle), not necessarily by bleed severity alone; c) Although 
patients reported a loss of utility during a bleed, they gradually regained the same 
level of utility/function, hence disability was not perceived as a linear process; d) Adult 
patients reported that nowadays, unlike them, children with hemophilia receiving 
prophylactic treatment are able to play sports (eg, ice hockey), thereby having better 
quality of life, an aspect not captured by standard utility instruments; e) Although 
caregiver-administered instruments for assessing quality of life in children with hemo-
philia are available, caregivers noted concern about accurately rating their child’s 
health status based on their experience. CONCLUSIONS: Although qualitative, 
patients’ perspectives revealed in this focus group demonstrated important utility 
consequences for the economic model that are not represented in the literature.
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LARGE-SCALE, PROSPECTIVE, OBSERVATIONAL STUDIES IN PATIENTS 
WITH PSORIASIS AND PSORIATIC ARTHRITIS: A SYSTEMATIC AND 
CRITICAL REVIEW.
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UK, 3Novartis Pharma AG, Basel, Switzerland
BACKGROUND: Observational studies, if conducted appropriately, play an impor-
tant role in the decision-making process providing invaluable information on effective-
ness, patient-reported outcomes and costs in a real-world environment. OBJECTIVES: 
A systematic review of large-scale, prospective, cohort studies with the aim of (a) 
summarising design characteristics, the interventions or aspects of the disease studied 
and the outcomes measured and (b) investigating methodological quality. METHODS: 
We included prospective, cohort studies which included at least 100 adults with 
psoriasis or psoriatic arthritis. Studies were identiﬁed through searches in electronic 
databases (Pubmed, Medline, Cochrane library, Centre for Reviews and Dissemina-
tion). Information on study characteristics were extracted and tabulated and quality 
assessment, using a checklist of 18 questions, was conducted.RESULTS: Thirty ﬁve 
papers covering 16 cohorts met the inclusion criteria. There were 10 treatment-related 
studies, only 2 of which provided a comparison between treatments, and 6 non-
treatment studies which examined a number of characteristics of the disease including 
mortality, morbidity, cost of illness and health-related quality of life. All studies 
included a clinical outcome measure and 11 included patient-reported outcomes, 
however only two studies reported information on patient utilities and two on costs. 
Quality ranged from 41% to 89%. Studies did well on a number of quality assessment 
questions including having clear objectives, documenting selection criteria, providing 
a representative sample, deﬁning interventions/characteristics under study, deﬁning 
and using appropriate outcomes, describing results clearly and using appropriate 
statistical tests. The quality assessment criteria least adhered to involved questions 
regarding sample size calculations, describing potential selection bias, deﬁning and 
adjusting for confounders and losses to follow-up, and deﬁning and describing a 
comparison group. CONCLUSIONS: The review highlights the need for well designed 
prospective observational studies on the effectiveness, patient-reported outcomes and 
economic impact of treatment regimes for patients with psoriasis and psoriatic arthritis 
in a real-world environment.
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PCASE1
UTILIZING EVIDENCE FROM DIFFERENT LEVELS IN THE 
REIMBURSEMENT PROCESS OF NEW MEDICAL TECHNOLOGIES–
ADVANCED RENAL CELL CARCINOMA FIRST LINE THERAPY IN 
POLAND 2008–2009
Matusewicz W, Baran J, Farkowski MM
Agency for Health Technology Assessment in Poland, Warsaw, Poland
ORGANIZATION: Agency for Health Technology Assessment in Poland (AHTAPol) 
serves as an advisory body to support the Minister of Health and relevant policy 
makers in the decision-making process in the public sector of health care in a 38 
million people country. PROBLEM OR ISSUE ADDRESSED: During 2007 in Poland, 
patients with metastatic renal cell carcinoma (mRCC), seventh-leading cause of death 
in men and in ninth-leading cause in women due to cancer, had access only to immu-
nomodulatory therapy. GOALS: Necessity of providing access to cost-effective new 
treatments in the ﬁrst line of therapy of mRCC. OUTCOMES ITEMS USED IN THE 
DECISION: Clinical efﬁcacy, safety, evidence from different levels of reliability (RCT, 
RCT interim analysis, patient registry), quality of life, cost-effectiveness/ cost-utility 
IMPLEMENTATION STRATEGY: Consultative Council (CC) of AHTAPol debated 
on the subject multiple times and given a new decision after each manufacturer’s 
submission comprised of a new HTA report updated as soon as the newest evidence 
was published RESULTS: In 2008–2009, CC debated over 3 claims for the reimburse-
ment of sunitinib and one for the reimbursement of bevacizumab in the indication: 
ﬁrst line treatment of mRCC. The ﬁrst submission on sunitinib, was based on an 
interim analysis of an international multicenter III phase randomized controlled trial 
(RCT) and 4 observational studies. The claim was rejected, on April 1, 2008, on the 
grounds of insufﬁcient data on overall survival (OS) and inacceptable level of cost-
effectiveness of app. USD 330 thousand per LYG, much higher than three-fold GDP 
recommended by WHO. The second submission, containing evidence from the ﬁrst 
submission together with ﬁnal results of the III phase trial available as conference 
presentation and abstract, was also rejected by CC on October 28, 2008. Claiming 
that a conference presentation and abstract are not sufﬁciently reliable evidence, CC 
concluded that no new evidence was presented and cost-effectiveness remained unac-
ceptably high. Meanwhile, August 6, 2008, CC rejected submission of bevacizumab 
on the grounds of unacceptably low level of submitted HTA report, especially in the 
sections comprising safety issues and economical analysis. Third and ﬁnal submission 
on sunitinib was debated on March 2, 2009. CC was presented the evidence from two 
previous submissions and a newly published data of BC Cancer Registry—a registry 
of patients with mRCC. This data on practical effectiveness showing prolongation of 
OS, rather that unreliable evidence on efﬁcacy derived from conference materials, 
persuaded CC to recommend reimbursement of sunitinib for Polish patients. After 
that crucial decision, National Health Fund created a dedicated therapeutic program 
for patients with mRCC with sunitinib as a ﬁrst line treatment. On December 12, 
2009 CC rejected second submission of bevacizumab because there was no evidence 
of its superiority over already reimbursed sunitinib. LESSONS LEARNED: Utilizing 
evidence from different levels can broaden decision maker’s perspective and justify 
coverage of sometimes expensive but socially demanded new treatments. In certain 
cases, there is a lack of evidence from the irrefutably well designed and conducted 
clinical controlled trials and thorough analysis of observational studies can give 
enough additional data to issue an informed decision. Data from large patient regis-
tries can be crucial to the decision-making process.
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DEVELOPING CRITERIA FOR USE FOR CONTINUOUS GLUCOSE 
MONITORING (CGM) SENSORS IN A VETERAN POPULATION
Christopher ML1, Bounthavong M1, Mendes M1, Kazerooni R1, Herbst KL2, Mavian AA2, 
Kung J2
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ORGANIZATION: Veteran Affairs San Diego Healthcare System (VASDHS) is a 
242-bed medical facility that provides comprehensive medical, surgical, mental health, 
rehabilitation, spinal cord injury, and extended care services for over 57,000 veterans. 
VASDHS is part of the Department of Veterans Affairs which is an integrated health 
care organization that operates using a national formulary, provides outpatient and 
inpatient specialty services and uses a comprehensive electronic medical record system. 
PROBLEM OR ISSUE ADDRESSED: The absence of an accepted system for evaluat-
ing appropriate utilization of disposable medical supplies present decision makers with 
concern for how resources are managed in this category of budget expenditures. There 
is no current standard in place for technology assessments for durable medical equip-
ment (DME) requiring disposable medical supplies in a pharmacy beneﬁt management 
(PBM) plan with the potential for extensive budgetary and utilization management 
challenges to our health care system. With the introduction of CGM to the US market, 
the American Diabetes Association has recognized CGM as a useful tool for clinicians 
and patients. Local health care systems are now faced with identifying the speciﬁc 
utility of this new technology for their patient population. GOALS: (1) Develop health 
technology criteria for use for CGM sensors (2) Assess diabetes outcomes after patients 
are approved for CGM device and sensors. OUTCOMES ITEMS USED IN THE 
DECISION: Clinical efﬁcacy/effectiveness included: HbgA1c (pre-post CGM sensors 
utilization), incidence of hypoglycemia, and Emergency Department and hospital 
admissions due to hypoglycemia. IMPLEMENTATION STRATEGY: The local Phar-
macy and Therapeutics (P&T) committee approved a criterion for use (CFU) for the 
CGM sensors that required providers to measure clinical efﬁcacy and patient outcomes 
in order to facilitate the decision making process for authorization. The pharmacy 
service implemented the P&T committee CFU in conjunction with a medical staff 
reviewer from our national headquarters for approval of the DME device. RESULTS: 
Twelve out of 15 patients who received the CGM devices were evaluable at 6 months. 
All patients were on insulin (100%), most were diagnosed with type I diabetes (92%), 
83% had hypoglycemia unawareness, and there was an average reduction of 0.13% 
HbgA1c following CGM intervention. No incidences of hypoglycemic events requiring 
hospitalizations occurred following the receipt of CGM, with 67% of patients report-
ing a reduction in frequency of hypoglycemic episodes. The average time to patient 
receipt of device was 90 days (d) (SD 76 d, median 73 d) from date of provider request. 
Fiscal Year 2009 (FY2009) VASDHS Pharmacy budget impact was estimated as 
$18,480. Annualized cost for CGM device and sensors ranged from $740 to $3520 
per patient based on patients reﬁll rates in FY2009. LESSONS LEARNED: There was 
a gap in communication that was identiﬁed within the CGM device approval process. 
Final decisions by the reviewer were not communicated to the provider who initiated 
the request for the CGM device in a timely manner. This led to a delay in getting 
patients the CGM devices. Hypoglycemic events that require hospitalization is a 
preventable economic burden to the PBM and society. CGM devices showed beneﬁt 
in eliminating unnecessary hospitalizations due to hypoglycemia and reducing the 
frequency of hypoglycemic events by alerting patients of the potential danger prior to 
it evolving in to a major problem.
